We are live on ! Find out more
VRDN icon

Viridian Therapeutics
VRDN

165 hedge funds and large institutions have $1.98B invested in Viridian Therapeutics in 2024 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 66 increasing their positions, 41 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

900% more funds holding in top 10

Funds holding in top 10: 1 → 10 (+9)

175% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 16

118% more capital invested

Capital invested by funds: $906M → $1.98B (+$1.07B)

61% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 41

20% more funds holding

Funds holding: 138 → 165 (+27)

4.75% more ownership

Funds ownership: 109.13% → 113.88% (+4.8%)

8% more call options, than puts

Call options by funds: $13.9M | Put options by funds: $12.9M

Holders
165
Holders Change
+27
Holders Change %
+19.57%
% of All Funds
2.37%
Holding in Top 10
10
Holding in Top 10 Change
+9
Holding in Top 10 Change %
+900%
% of All Funds
0.14%
New
44
Increased
66
Reduced
41
Closed
16
Calls
$13.9M
Puts
$12.9M
Net Calls
+$1.01M
Net Calls Change
+$3.94M

Top Buyers

1
DCM
Driehaus Capital Management
Illinois
+$32.6M
2
EC
EcoR1 Capital
California
+$32M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$26.3M
4
FFM
Fairmount Funds Management
Pennsylvania
+$26.2M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$19.7M

Top Sellers

1
MC
Maverick Capital
Texas
-$21.4M
2
PCH
Polar Capital Holdings
United Kingdom
-$11.6M
3
GTC
Ghost Tree Capital
New York
-$8.38M
4
RI
RTW Investments
New York
-$7.88M
5
State Street
State Street
Massachusetts
-$6.42M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$254M +$26.3M +1,610,130 +17%
BlackRock
2
BlackRock
New York
$109M +$497K +30,384 +0.6%
Vanguard Group
3
Vanguard Group
Pennsylvania
$101M +$17.6M +1,074,366 +32%
VA
4
VR Adviser
New York
$88.3M +$621 +38 +0%
DTC
5
Deep Track Capital
Connecticut
$85.3M -$2.83M -172,904 -4%
FFM
6
Fairmount Funds Management
Pennsylvania
$78.4M +$26.2M +1,600,000 +87%
PBA
7
Paradigm Biocapital Advisors
New York
$65.9M -$10.8K -660 -0%
PA
8
Perceptive Advisors
New York
$64M +$19.3M +1,180,837 +72%
CC
9
Commodore Capital
New York
$58M +$361K +22,092 +0.9%
KCM
10
Kynam Capital Management
New Jersey
$57.1M +$12.4M +761,295 +44%
NHAS
11
Novo Holdings A/S
Denmark
$54.3M +$6.29M +385,000 +19%
State Street
12
State Street
Massachusetts
$54.1M -$6.42M -392,605 -14%
TCM
13
Tang Capital Management
California
$51M +$13.9M +850,000 +61%
AllianceBernstein
14
AllianceBernstein
Tennessee
$50.1M +$3.34M +204,547 +10%
MC
15
Maverick Capital
Texas
$45.4M -$21.4M -1,310,792 -40%
DCM
16
Driehaus Capital Management
Illinois
$45.3M +$32.6M +1,991,490 New
EC
17
EcoR1 Capital
California
$44.6M +$32M +1,958,847 New
VC
18
Vivo Capital
California
$38.2M – – –
Geode Capital Management
19
Geode Capital Management
Massachusetts
$34M +$1.34M +81,951 +6%
Adage Capital Partners
20
Adage Capital Partners
Massachusetts
$27.4M +$19.7M +1,205,000 New
Pictet Asset Management
21
Pictet Asset Management
Switzerland
$23.3M +$52.9K +3,233 +0.3%
Morgan Stanley
22
Morgan Stanley
New York
$23M +$11.3M +689,309 +215%
OCA
23
Octagon Capital Advisors
New York
$19.8M +$4.09M +250,000 +40%
YCM
24
Yiheng Capital Management
California
$19.3M -$1.64M -100,239 -11%
WP
25
Woodline Partners
California
$18.6M +$6.84M +418,080 +104%
1
2 3 4 5

VRDN Hedge Fund Activity: Q3 2024 in Review

165 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q3 2024, worth a combined $1.98B — up 118% from $906M a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new VRDN positions and 16 closed out — a net gain of 28 holders — while 66 added to existing stakes and 41 trimmed.

The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $32.6M. The largest seller was Maverick Capital, cutting an estimated $21.4M.

  • 165 institutional investors held Viridian Therapeutics (VRDN) as of Q3 2024, up from 138 in Q2 2024.
  • Funds reported $1.98B of Viridian Therapeutics stock for Q3 2024, up 118% quarter-over-quarter.
  • 44 funds opened new Viridian Therapeutics positions in Q3 2024 and 16 closed out, a net change of +28 holders.
  • The largest Viridian Therapeutics buyer in Q3 2024 was Driehaus Capital Management, an estimated $32.6M added.
  • The largest Viridian Therapeutics seller in Q3 2024 was Maverick Capital, an estimated $21.4M sold.

Based on aggregated 13F filings for Q3 2024.